Shares of Sarepta Therapeutics (NASDAQ: SRPT) rose 24% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The biotech company, which focuses on precision gene therapies, closed out at $123.06 a share last week, then rose to a 52-week high of $152.30 on Wednesday. The catalyst for the move up was the company's fourth-quarter and full-year earnings report, or rather something that was in it.

Sarepta's revenue numbers were up for the quarter and for the year, and its earnings per share (EPS) improved in the quarter, if not for the year. It wasn't the company's financials, though, that spurred the stock, but news regarding the company's gene therapy, SRPT-9001.

The company, in its earnings release on Tuesday, said it had been told that the Food and Drug Administration isn't requiring an advisory committee meeting regarding the therapy, meaning SRPT-901 may be on an accelerated approval process as a therapy to treat Duchenne muscular dystrophy.

Continue reading

Source Fool.com